Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects Who Relapsed After Previous Interferon-based Therapy
Brief Summary: The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in patients who are infected with genotype 1 hepatitis C virus who relapsed after previous interferon-based therapy. Patients will also receive peginterferon alfa-2a and ribavirin as part of their treatment.


Options:
A: Arm Label: SOF+RBV; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match SOF, Drug: Placebo to match RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): Placebo
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: 12 Week Cohort; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: 16 Week Cohort; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort, Control | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 12 Week Cohort, 16 Week Cohort, Control
C: Arm Label: 1. Placebo + PEG + RBV; Type: PLACEBO_COMPARATOR; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Placebo | Arm Label: 2. Boceprevir + PEG + RBV - 24 Weeks (RGT); Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Arm Label: 3. Boceprevir + PEG + RBV - 44 Weeks; Type: EXPERIMENTAL; Interventions: Biological: Peginterferon alfa-2b (PEG), Drug: Ribavirin (RBV), Drug: Boceprevir | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2b (PEG); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): 1. Placebo + PEG + RBV, 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1. Placebo + PEG + RBV | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): 2. Boceprevir + PEG + RBV - 24 Weeks (RGT), 3. Boceprevir + PEG + RBV - 44 Weeks
D: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a (PegIFN alpha-2a), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Peginterferon alpha-2a (PegIFN alpha-2a); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435

Answer: D